Deficiency in antithrombin III is seen in approximately 2% of patients with venous thromboembolic disease
This can reduce neuroinflammation, a key factor in TBI and concussion, and promote cellular repair throughout the brain and body
[21] Hu Y, et al
The primary antibodies used included anti-phospho-Smad2, anti-phospho-Smad3, anti-Smad2/3 complex, and anti-GAPDH (all purchased from Cell Signaling Technology, Danvers, MA, U.S.A.)
TBI-induced ischemia, due to reduced CBF or microvascular damage that impedes blood glucose delivery despite preserved CBF, causes increased utilization of all these energy sources, which subsequently stresses cellular glucose/glycogen/lactate stores within the first few hours after injury [39, 59, 60]
In addition, starting with a conservative Pt141 dosage helps gauge how the body responds to the compound